Eyenovia acquires u.s. commercial rights to app13007 (clobetasol propionate ophthalmic nanosuspension, 0.05%) from formosa pharmaceuticals

App13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery
EYEN Ratings Summary
EYEN Quant Ranking